The medication is generally used to provide supportive symptomatic relief across key domains where discomfort is significant. The medicine is utilized for severe pain and fever in situations where patients experience pronounced discomfort, and to address pain related to heightened physiological activity.

Supportive Symptomatic Relief for Severe Acute Pain

This combination is applied in clinical settings that involve acute or unstable symptom patterns, primarily for severe pain that creates noticeable physiological strain. It is relevant for easing symptoms associated with post-traumatic pain, pronounced headaches, neuralgia, and postoperative discomfort. The medication supports managing symptoms that interfere with daily comfort.

Management of Pain Coupled with Fever and Spasm

This compound is commonly used across conditions presenting with acute episodes involving a challenging cluster of symptoms, specifically the combination of intense discomfort and high, persistent fever. It is also applied in addressing pain driven by heightened physiological activity in conditions like colic. This formulation offers symptomatic relief that helps patients cope more steadily with symptom fluctuations, and assists with easing the overall symptom load.

---

Quick Fact: Relief for Combined Symptoms The combination is considered relevant for easing symptomatic manifestations when the patient experiences both severe pain and persistent fever concurrently, often applied in scenarios where short-term symptomatic assistance is needed, assisting with maintaining comfort during symptomatic phases.

The eligibility to use the combination medicine Анальдим (containing Metamizole Sodium and Diphenhydramine) is highly restricted by official government regulatory documents, which list numerous absolute contraindications.

Contraindicated Populations

Official labeling mandates that this medicine must not be used by the following groups:

• Age and Reproductive Status: Children under the age of 15 years, pregnant women, and women who are breastfeeding.
• Hypersensitivity: Individuals with known allergy or increased sensitivity to the active components (Metamizole or Diphenhydramine) or to other pyrazolone derivatives.

Absolute Eligibility Exclusions

Use is formally prohibited for patients with the following pre-existing conditions, as documented in official prescribing information:

System/Condition	Exclusion Type
Hematopoietic	Blood disorders (e.g., agranulocytosis, leukopenia), or Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.
Organ Function	Severe impairment of liver or kidney function.
Gastrointestinal	Active or stenosing peptic ulcer disease.
Other Conditions	Glaucoma, bronchial asthma, certain cardiac rhythm disorders, congenital long QT syndrome, epilepsy, or prostatic hyperplasia.

Eligibility to use this medicine is strictly defined by the absence of all listed conditions and falling within the approved age range.

The official regulatory profile for Анальдим defines interactions across pharmacokinetic and pharmacodynamic domains. The Sodium Metamizole component is a documented metabolic modulator, functioning as a moderate to strong inducer of several liver enzymes, including CYP3A4, CYP2B6, and CYP2C19. This induction pathway is associated with reduced systemic exposure and lower concentrations of co-administered medicines that are substrates for these enzymes, such as Cyclosporine, Midazolam, and Sertraline.

The Diphenhydramine component's profile highlights interactions related to additive systemic effects. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally restricted due to the risk of potentiated anticholinergic effects. Additionally, Diphenhydramine contributes to additive CNS depression when combined with alcohol or other central nervous system depressants.

Interaction Type	Interacting Substance	Official Regulatory Outcome
CYP Induction (Metamizole)	Cyclosporine, Midazolam	Decreased systemic concentration/exposure
Pharmacodynamic	Alcohol, CNS Depressants	Additive CNS depressive effects

A mandatory time separation in administration is required when co-administering with Acetylsalicylic acid (Aspirin) to prevent the Metamizole component from interfering with Aspirin's anti-platelet effect. A heightened risk of interaction-related outcomes, such as increased sedation, is officially noted for elderly patients and those with hepatic or renal impairment.

Central Inhibition of Nociceptive and Thermoregulatory Signaling

This domain describes the primary action of the drug's metabolites, focusing on the selective inhibition of cyclooxygenase-3 ( COX-3) in the central nervous system (CNS). This enzyme blockade reduces the synthesis of central Prostaglandin E2 ( PGE2), a key signaling molecule. This cascade results in analgesic and antipyretic effects via the modulation of nociceptive signaling and hypothalamic thermoregulation.

---

Modulation of Endogenous Pain Control Pathways

Beyond enzyme inhibition, the drug's mechanism engages the body's native pain pathways by activating CB1 receptors and modulating the opioidergic system in the CNS. This synergistic action augments descending pain inhibitory signals, contributing to the dampening of nociceptive transmission.

---

Direct Smooth Muscle Ca^2+ Modulation

This distinct mechanistic domain is mediated by the drug’s ability to interfere with intracellular Ca^2+ release pathways (specifically, via inositol phosphate) within smooth muscle cells. This action causes the direct relaxation of hypertonic smooth muscle, resulting in an anti-spasmodic effect (modulation of muscle tension in visceral smooth muscle tissues).

The administration of Анальдим, a fixed-dose combination product, is structured according to established protocols defining the route, dose limits, frequency, and duration of use. The medicine is approved for administration via the oral route (tablets), the rectal route (suppositories), and the parenteral route (intramuscular or intravenous solution for injection). The choice of route is determined by the specific formulation used.

Dosing is constrained by the maximums for both components. For the primary analgesic component, Sodium Metamizole, the single dose is limited to 1,000 mg, with the maximum total daily intake not exceeding 4,000 mg when given orally. Administration occurs on an as-needed basis for acute symptoms, up to four times daily, provided a minimum time interval of six to eight hours is maintained between doses. The use of this medicine is designated as short-term symptomatic management only.

Specialized instructions govern the parenteral use of the injectable solution. Intravenous administration requires the solution to be injected slowly and often necessitates a supervised clinical setting. Furthermore, dose modifications are a mandatory part of the usage protocol for specific patient populations. Dosing for older adults, as well as patients presenting with hepatic or renal impairment, requires a reduction in the administered dose or an extension of the time interval between doses. Pediatric dosing is weight-dependent and must follow a mg/kg calculation.

Research evidence / Overview of studies for Анальдим

1. Evidence for Use in Managing Severe Acute Pain

The research investigating symptom patterns in acute pain was evaluated primarily in Randomized Controlled Trials (RCTs) and Systematic Reviews focusing on the main component, Sodium Metamizole. These studies were applied in research contexts involving fluctuating or unstable symptoms, such as post-operative pain or acute headaches. Researchers used these trials to examine symptom intensity or variability, recording patient-reported outcomes describing perceived discomfort using standardized pain scales.

Research exploring short-term symptom changes describes the patterns of symptom measurements in the observed populations. Findings describe patterns observed in the studies related to the speed of pain relief measurements and the duration over which a measured change was observed. The evidence contributes to the broader evidence landscape of research examining short-term pain symptoms.

Despite this body of evidence for the main ingredient, comparative evidence is lacking for the fixed-dose combination of Metamizole and Diphenhydramine. Therefore, the research describing patterns related to the combined effect of analgesia and the auxiliary calming action is limited.

---

2. Evidence for Use in Reducing High and Persistent Fever

Research exploring outcomes related to temperature changes for fever was studied through a range of RCTs and observational settings. Studies examined outcomes related to systemic or functional imbalance by measuring core body temperature and observing how quickly that temperature changed and the length of time the change was recorded. Research monitored fever in both adult and child populations, using study designs that included comparisons to other antipyretic medicines.

Studies describe the patterns of symptom measurements in the observed populations, indicating changes in temperature readings over defined, short time intervals following administration. Research provides insight into short-term changes in symptom patterns.

What remains uncertain is the specific role of the Diphenhydramine component in this context. While the main ingredient's outcomes were observed, the research provides limited context regarding any additional benefit or impact that the combination’s secondary ingredient may offer for the temperature measurement itself.

---

3. What is Still Uncertain About Анальдим

The available research primarily explores acute changes and short-term symptom patterns, with follow-up durations often limited to a few hours or days. Therefore, outcomes related to chronic symptoms, prolonged use, or the durability of measured effects are not well established.

Comparative evidence is lacking between the combination product and the primary ingredient used alone. Additionally, data for certain special patient groups, such as older adults with multiple concurrent conditions, remain insufficient. Evidence quality varies across studies, and findings were mixed or inconsistent for some highly specific uses, underscoring that the overall understanding of the medicine's outcomes beyond short-term symptomatic relief is still emerging.

Key Studies & References

1. Safety Profile of Metamizole – A Systematic Review
2. Parenteral Ready-to-Use Fixed-Dose Combinations Including NSAIDs with Paracetamol or Metamizole for Multimodal Analgesia—Approved Products and Challenges (Review on FDCs)

Common questions about Анальдим (FAQ)

Q: What exactly is Analdim prescribed for?

Official product information states that the primary ingredient, Metamizole, is authorized in various regions for the management of acute severe pain. This pain can include symptoms experienced after surgery or injury, as well as certain types of tumor pain. It is also authorized to help reduce high fever when other treatments have not been successful.

Q: Is Analdim a strong medicine or a weak one?

Regulatory summaries indicate that the main ingredient, Metamizole, is pharmacologically classified as a potent analgesic (pain reliever). In addition to its powerful pain-relieving effects, official sources describe it as having antipyretic (fever-reducing) and spasmolytic (smooth muscle relaxing) properties.

Q: Does Analdim only help with pain or also with inflammation?

Official information describes the active ingredient, Metamizole, primarily as a pain-relieving, fever-reducing, and spasm-relieving agent. Compared to traditional Non-Steroidal Anti-inflammatory Drugs ( NSAIDs), studies indicate that the medicine has weak or limited properties related to treating inflammation.

Q: How long after taking Analdim does it start working?

Pharmacokinetic studies, which examine how the medicine moves through the body, provide an indication of onset. Official documents report that the main active substances from the primary ingredient typically reach their peak concentration in the bloodstream within 1.2 to 2.0 hours following oral administration.

Q: How long does the effect of one dose of Analdim last?

The duration of the medicine's components in the body is described by their elimination half-life. For the Diphenhydramine component, this period typically ranges from 2.4 to 9.3 hours in healthy adults. This half-life measurement provides a reference point for how long the substance remains active in the body.

Q: Why is Analdim sold by prescription only in some countries?

The regulatory classification of the primary ingredient, Metamizole, differs significantly around the world. In regions such as the US and the UK, the medicine is restricted to prescription-only use or banned due to documented risks, primarily the rare but serious condition known as agranulocytosis. Other countries, however, permit its sale over-the-counter.

Q: Is there a risk of Analdim interacting with vitamins or supplements?

The Diphenhydramine component has a sedative effect that may combine with the effects of certain dietary supplements or vitamins. Official safety statements note the potential for additive side effects, which can include increased sleepiness or drowsiness.

Q: Are there side effects that appear not immediately, but over time?

Official safety documentation indicates that certain serious adverse reactions are not limited to the immediate period following administration. For example, severe conditions such as agranulocytosis (a serious drop in white blood cells) or liver injury may be documented to occur at any point during treatment, or even shortly after the medicine has been discontinued.

Q: Does Analdim affect driving a car?

Regulatory warnings confirm that the Diphenhydramine component can cause central nervous system ( CNS) depression. These effects include symptoms like sedation, dizziness, and impaired psychomotor function (physical movements). Official product information states that these documented effects affect a person’s ability to drive or operate complex machinery.

Q: What are the signs that Analdim is not suitable for me?

Regulatory documents define strict safety limits, and signs of the medicine being unsuitable are related to documented serious reactions. These include any symptoms of a severe allergy, such as difficulty breathing, swelling, or a spreading rash. Additionally, signs of potential agranulocytosis, such as persistent fever, mouth sores, or sore throat, are classified in regulatory documents as serious adverse events.

Q: Have the official recommendations for the use of Analdim changed in recent years?

The regulatory guidance for the primary ingredient, Metamizole, has seen historical changes, with certain countries banning or significantly restricting its use over time. More recently, bodies like the EMA have issued safety updates to address known risks, ensuring the product is used in alignment with the latest data.

Q: Can I take Analdim if I have high blood pressure?

The Diphenhydramine component is listed under precautions in official product information for individuals who have pre-existing cardiovascular conditions, including hypertension (high blood pressure). This general regulatory advice applies because certain medications can affect the cardiovascular system.

Q: Why is Analdim effective for some types of pain but not others?

The unique formulation is documented to provide both pain relief (analgesia) and a specific spasmolytic effect, meaning it helps relax hypertonic smooth muscles. Studies and official documents note that this action makes the medicine suitable for managing severe pain, including colicky or spasmodic pain.

Q: Does Analdim affect blood or urine test results?

Yes, official safety warnings indicate that the primary component, Metamizole, has been shown to interfere with laboratory testing. It can affect the accurate measurement of common biochemical tests, such as those for creatinine, uric acid, and cholesterol. This interference can potentially lead to falsely lowered results.

Q: What happens in case of accidental Analdim overdose?

Official regulatory literature and clinical reports detail the risks of accidental overdose for the active ingredients. Symptoms can include excessive drowsiness, confusion, rapid heartbeat, vomiting, and potential renal impairment. Management of overdose symptoms involves supportive treatment and is conducted under the care of medical professionals.

Q: What symptoms indicate that Analdim is interacting with another medicine?

When taken with other substances, particularly alcohol or central nervous system ( CNS) depressants, the interaction may result in noticeable symptoms. Official warnings cite that an interaction could manifest as excessive drowsiness, sedation, dizziness, or impaired focus, highlighting an additive effect.

Q: Are there restrictions on combining Analdim with herbal teas or preparations?

Official safety information for the Diphenhydramine component notes the potential for an interaction when combined with certain herbal teas or preparations. This is because many herbal remedies have a known calming effect, and the combination could lead to undesirable additive side effects, such as heightened sedation.

Q: Can Analdim cause dry mouth?

Yes, dry mouth is a documented side effect of the medicine. This is primarily attributed to the anticholinergic properties of the Diphenhydramine component. The symptom is also listed in regulatory reviews as a potential adverse effect of the primary ingredient, though its frequency may not always be established.

How to Store and Dispose of Analgin (Metamizole Sodium + Diphenhydramine)

Official regulatory documents define strict conditions for the storage and disposal of Analgin to maintain its stability.

Storage Requirements

Condition	Requirement
Temperature	Store at a temperature not exceeding 25 C; specific suppository forms may require 8 C to 15 C or refrigeration.
Protection	Keep the medicine in the original packaging to protect from light. Injection solutions must be protected from freezing.
Safety	The product must be stored out of the sight and reach of children.
Stability	Do not use the medicine after the expiration date stated on the packaging.

Disposal Instructions

Unused or expired Analgin must be disposed of in accordance with local legal requirements for pharmaceutical waste. Medicine should not be discarded via wastewater or household rubbish unless specifically directed by local authority take-back programs.